Asset 41

Get Control Over
Clinical Trial Planning

VISIONAL™ has been a game-changer since 2022, and with these new updates, it’s setting the industry standard. AI doesn’t replace expertise — it supercharges it. 

And clinical research needs it now more than ever.

PSI CRO's proprietary cloud-based platform.

INTELIA™ brings together a suite of clinical trial planning tools:

  • VISIONAL™ study modeling tool
  • CLARITY™ study budgeting and forecasting
  • CADENCE™ study budget tracking tool
  • INSITE™ investigator grant calculator
  • PACE™ smart monitoring planning

VISIONAL™: Helping to Accurately Predict Study Enrollment Timelines

VISIONAL™ is an AI-powered system for feasibility and enrollment forecasting. It’s part of PSI’s INTELIA™ platform, a suite of advanced tools for clinical trial modeling and planning. Using different internal and external data sources, VISIONAL™ models and compares hundreds of enrollment scenarios, their budgets and probability of success for your protocol.

How it Works

VISIONAL™ is an AI-powered system for feasibility and enrollment forecasting. It’s part of PSI’s INTELIA™ platform, a suite of advanced tools for clinical trial modeling and planning.

Using different internal and external data sources, VISIONAL models and compares hundreds of enrollment scenarios, their budgets and probability of success for your protocol.

The goal is to find the right combination of countries and sites and the optimal study duration and budget. We typically analyze 40-60 countries for each phase II and phase III study, pulling internal and external data for each one. We use AI to find the right match quickly, but our medically trained feasibility team always validates the selection, to make sure the data is relevant for your protocol design.

The data also varies: we collect and incorporate SoC/local access to certain treatments, site interest (if available), feasible start-up ranges per country, and any regulatory limitations.

The key data points for modeling are site performance and historical enrollment rates for similar designs and indications. We use our own country performance data and some of the industry’s largest databases.

For budget predictions, we trained our algorithms on the CLARITY™ data, so VISIONAL™ can quickly simulate different budget scenarios.

For your protocol, we can provide

  • the fastest possible patient enrollment scenario
  • cost-effective enrollment options
  • optimal patient enrollment scenarios that balance out associated costs and study duration

VISIONAL™ can also be used to validate your requested specifications, to estimate probability of success for the expected scenarios, and to recommend alternatives.

Immediate & Long-Term Benefits

Modeling Beyond Human Abilities 

VISIONAL™ is extremely fast: it has the capacity to model and compare hundreds of possible enrollment scenarios and suggest the most optimal scenario within only a few minutes

Predictions without Human Errors and Bias: VISIONAL™ de-biases enrollment projections: scenarios are automated and data-driven

Probability Projections: VISIONAL™ estimates the probability of enrollment projections using historical data

Up-to-date Algorithms: VISIONAL™ is up to date: the algorithms are based on the latest data and are being “retrained” on an ongoing basis to capture the latest insights

Live Budget Simulations: VISIONAL™ incorporates costs in the decision-making process

INTELIA™ in the News

Webinar

Clinical and Financial Feasibility Forecasting in One: PSI VISIONAL™

Press Release

PSI Expands VISIONAL™ GenAI Feasibility Capabilities for Fast, Flexible and Reliable Clinical Trial Planning

teal square with visional
Video

VIDEO: VISIONAL™: Study Modeling Tool From PSI CRO 

Case Study

Case Study: How VISIONAL™ is Helping to Accurately Predict Study Enrollment Timelines

Take Clinical Trial Proposals
to a Whole New Level
of Dependability

Model multiple enrollment scenarios for phase II and III trials already at the RFP stage, compare study costs, and select the optimal realistic solution within minutes.